Efficacy of Disitamab Vedotin versus chemotherapy in the treatment of advanced bladder cancer
10.12483/j.issn.1009-8291.2026.04.005
- VernacularTitle:维迪西妥单抗对比化疗在治疗晚期膀胱癌患者中的疗效分析
- Author:
Xuyan GUO
1
;
Fuxun ZHANG
1
;
Yunhua JI
1
;
Bo ZHANG
1
Author Information
1. Department of Urology, Tangdu Hospital, Air Force Medical University, Xi'an 710038, China
- Publication Type:Journal Article
- Keywords:
advanced bladder cancer;
antibody-drug conjugate;
Disitamab Vedotin;
Toripalimab;
chemotherapy
- From:
Journal of Modern Urology
2026;31(4):319-326
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the differences in the efficacy and safety between antibody-drug conjugate(ADC)combined with programmed cell death 1(PD-1)inhibitor and chemotherapy in the treatment of advanced bladder cancer based on real-word data, so as to provide reference for individualized treatment regimens. Methods Clinical data of 107 patients pathologically diagnosed with bladder urothelial carcinoma admitted to our hospital during Jan.13, 2022 and Dec.27, 2024 were retrospectively collected. All patients had lymph node and/or distant metastases confirmed by CT or PET/CT. Among them, 38 were treated with Disitamab Vedotin plus Toripalimab(Disitamab Vedotin group), and 69 were treated with Gemcitabine plus Cisplatin(GC, chemotherapy group). The short and long-term efficacy and treatment-related adverse events(TRAEs)were compared between the two groups. Results The objective response rate(ORR)was higher in the Disitamab Vedotin group than in the chemotherapy group(18.4% vs. 5.8%), with no statistically significant difference(P＞0.05). The disease control rate(65.8% vs. 33.3%), progression-free survival(9.35 months vs. 7.76 months)and overall survival(29.54 months vs. 12.33 months)were higher/longer in the Disitamab Vedotin group than in the chemotherapy group, with statistically significant differences(P＜0.05). TRAEs such as peripheral neuropathy(44.7%)and alopecia(36.8%)occurred in 35 patients(92.1%)in the Disitamab Vedotin group, while TRAEs including leukopenia(44.9%), nausea and vomiting(44.9%), and alopecia(42.0%)occurred in 65 patients(95.6%)in the chemotherapy group. Conclusion Compared with standardized chemotherapy, Disitamab Vedotin plus Toripalimab can significantly reduce the risk of disease progression or death in patients with advanced bladder cancer, with manageable safety.
